Seagen reports first quarter 2022 financial results

Bothell, wash.--(business wire)--seagen inc. (nasdaq:sgen) reported financial results today for the first quarter ended march 31, 2022. the company also highlighted padcev® (enfortumab vedotin-ejfv), tukysa® (tucatinib), adcetris® (brentuximab vedotin) and tivdak® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its deep and diverse oncology pipeline. “seagen delivered strong results for the first quarter of 2022 with net product sales increasing 2
SGEN Ratings Summary
SGEN Quant Ranking